Publications by authors named "Baiyong Li"

Claim this Profile
I
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.
Zhiwei Chen, Fang Yang, Zhou Jiang, Longhua Sun, Lin Wu, Xingya Li, Ying Liu, Pingli Wang, Jie Li, Shuliang Guo, Juan Li, Xuewen Liu, Zhengguo Li, Dairong Li, Jie Li, Hualin Chen, Wenting Li, Baiyong Li

Lancet· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of monoclonal antibody AK111 in the treatment of active ankylosing spondylitis: a randomised, double-blind, placebo-controlled, multicentre phase II clinical study.
Hua Ye, Shengyun Liu, Yongjun Mei, Jieruo Gu, Min Yang, Li Zhang, Baiyong Li, Zhanguo Li

Clin Exp Rheumatol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.
Lin Shen, Yanqiao Zhang, Ziyu Li, Xiaotian Zhang, Xiangyu Gao, Bo Liu, Ning Li, Mulin Liu, Zheng Liu, Wei Li, Changzheng Li, Lian Liu, Lixin Wan, Lili Sheng, Zhenyang Liu, Hao Liu, Ming Liu, Lin Xie, Xiaoqin Li, Haiyan Liu, Wenxin Li, Qingshan Li, Lizhu Lin, Wei Liu, Baiyong Li

Nat Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial.
Lin Shen, Yanqiao Zhang, Ziyu Li, Xiaotian Zhang, Xiangyu Gao, Bo Liu, Ning Li, Mulin Liu, Zheng Liu, Wei Li, Changzheng Li, Lian Liu, Lixin Wan, Lili Sheng, Zhenyang Liu, Hao Liu, Ming Liu, Lin Xie, Xiaoqin Li, Haiyan Liu, Wenxin Li, Qingshan Li, Lizhu Lin, Wei Liu, Baiyong Li

Nat Med· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Administration of a Novel Anti-NGF Monoclonal Antibody (AK115) in Healthy Participants: A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Clinical Trial.
Juan Zhang, Yu-Xin Fan, Yu Huang, Runfang Guan, Ruixia Li, Baiyong Li

Drug Des Devel Ther· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design of a fragment crystallizable-engineered tetravalent bispecific antibody targeting programmed cell death-1 and vascular endothelial growth factor with cooperative biological effects.
Tingting Zhong, Lingzhi Zhang, Zhaoliang Huang, Xinghua Pang, Chunshan Jin, Wenrong Liu, Baiyong Li

iScience· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.
Anwen Xiong, Lei Wang, Jianhua Chen, Lin Wu, Baogang Liu, Jie Li, Bolin Chen, Jinliang Wang, Ligong Nie, Gaofeng Li, Xingya Li, Yu Lin, Xuewen Liu, Baiyong Li

Lancet· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China.
Xiaohua Wu, Yang Sun, Hongying Yang, Jing Wang, Hanmei Lou, Dan Li, Yuzhi Li, Guiling Li, Dapeng Li, Xiumin Li, Lijing Zhu, Xianling Liu, Yunxia Li, Lihong Chen, Qingshan Li, Zhiqing Liang, Funan Liu, Meili Sun, Lina Hu, Guzhalinuer Abulizi, Sihai Liao, Ting Liu, Baiyong Li

Lancet· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab.
Yanyan Zhang, Zhaohui Pei, Beijian Chen, Yanling Qu, Xiaolin Dong, Baiyong Li

Pharmacol Res· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant: A Randomized Clinical Trial.

JAMA· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cadonilimab with chemotherapy in HER2-negative gastric or gastroesophageal junction adenocarcinoma: the phase 1b/2 COMPASSION-04 trial.
Xiangyu Gao, Ke Ji, Yongning Jia, Fei Shan, Ye Chen, Tianshu Liu, Changzheng Li, Xiaoyan Lin, Wei Liu, Baiyong Li, Lin Shen, Ziyu Li

Nat Med· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical imaging evaluation of a bispecific antibody targeting hPD1/CTLA4 using humanized mice.
Xingguo Hou, Song Liu, Ziqing Zeng, Zilei Wang, Jin Ding, Baiyong Li

Biomed Pharmacother· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Penpulimab, an anti-PD-1 antibody, for heavily pretreated metastatic nasopharyngeal carcinoma: a single-arm phase II study.
Xiaozhong Chen, Wei Wang, Qingfeng Zou, Xiaodong Zhu, Qin Lin, Liangfang Shen, Lin Wang, Xiaoyan Lin, Shaojun Lin, Minying Li, Ruilian Xu, Haifeng Lin, Wenting Li, Baiyong Li, Jingao Li

Signal Transduct Target Ther· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fc-Fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapies.
Weifeng Zhang, Xueling Chen, Xingxing Chen, Jirui Li, Hui Wang, Liangli Hong, Penghao Li, Yanyu Ling, Baiyong Li

J Immunother Cancer· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study.
Hanmei Lou, Hongbing Cai, Xin Huang, Guiling Li, Li Wang, Fei Liu, Ting Liu, Wei Liu, Baiyong Li

Clin Cancer Res· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of cadonilimab in previously treated recurrent or metastatic nasopharyngeal carcinoma(COMPASSION-06): A phase II multicenter study.
Qiu-Yan Chen, Shan-Shan Guo, Ying Luo, Song Qu, De-Hua Wu, Qin Lin, Shao-Jun Lin, Wei Liu, Bai-Yong Li, Lin-Quan Tang

Oral Oncol· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Sophia Frentzas, Anna Rachelle Austria Mislang, Charlotte Lemech, Adnan Nagrial, Craig Underhill, Baiyong Li

J Immunother Cancer· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase 1b Study of Ivonescimab, a Programmed Cell Death Protein-1 and Vascular Endothelial Growth Factor Bispecific Antibody, as First- or Second-Line Therapy for Advanced or Metastatic Immunotherapy-Naive NSCLC.
Lei Wang, Yongzhong Luo, Shengxiang Ren, Zhihong Zhang, Anwen Xiong, Baiyong Li

J Thorac Oncol· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer.
Bolin Chen, Wenxiu Yao, Xingya Li, Gen Lin, Qian Chu, Hailong Liu, Jie Lin, Liyu Liu, Li Xu, Kang Li, Jia Li, Baiyong Li, Lin Wu

Br J Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1/CTLA-4 bispecific antibody in patients with solid tumors.
Jianghua Wang, Xiaoting Li, Guanxi Xiao, Jayesh Desai, Sophia Frentzas, Baiyong Li

Cancer Immunol Immunother· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors.
Sophia Frentzas, Hui K Gan, Rasha Cosman, Jermaine Coward, Ben Tran, Baiyong Li

Cell Rep Med· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial.
Qian Qiao, Chun Han, Sisi Ye, Juan Li, Guoliang Shao, Meili Sun, Lijie Song, Ting Liu, Wei Liu, Baiyong Li, Li Bai

Front Immunol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, Pharmacokinetics and Preliminary Efficacy of IL4-Rα Monoclonal Antibody AK120 in Both Healthy and Atopic Dermatitis Subjects: A Phase I, Randomized, Two-Part, Double-Blind, Placebo-Controlled, Dose-Escalation, First-In-Human Clinical Study.
Christopher John Wynne, Alexandra Cole, Charlotte Lemech, Guoqin Wang, Yu Zhang, Baiyong Li

Dermatol Ther (Heidelb)· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study).
Yuanyuan Zhao, Yuxiang Ma, Yun Fan, Jianya Zhou, Nong Yang, Baiyong Li, Li Zhang

Lung Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial.
Xiangyu Gao, Nong Xu, Ziyu Li, Lin Shen, Ke Ji, Dan Liu, Li Bai, Tianshu Liu, Yunxia Li, Yuzhi Li, Xiaoyan Lin, Changzheng Li, Guiling Li, Lijing Zhu, Xiumin Li, Fenghu Li, Sihai Liao, Xiaofan Li, Jianjie Li, Xiaohong Liu, Wenting Li, Baiyong Li

Lancet Oncol· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis